SAN FRANCISCO, Dec. 27, 2022 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today announced the company will be participating in the upcoming 41st Annual J.P. Morgan Healthcare Conference.
iRhythm’s management is scheduled to present on Tuesday, January 10, 2023, at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time. Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company’s website at investors.irhythmtech.com.
About iRhythm Technologies, Inc.
iRhythm is a leading digital health care company that creates trusted solutions that detect, predict, and prevent disease. Combining wearable biosensors and cloud-based data analytics with powerful proprietary algorithms, iRhythm distills data from millions of heartbeats into clinically actionable information. Through a relentless focus on patient care, iRhythm’s vision is to deliver better data, better insights, and better health for all.
Investor Relations Contact:
Stephanie Zhadkevich
(919) 452-5430
This email address is being protected from spambots. You need JavaScript enabled to view it.
iRhythm Media Contact:
Morgan Mathis
(310) 528-6306
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$89.02 |
Daily Change: | 6.57 7.97 |
Daily Volume: | 529,200 |
Market Cap: | US$2.780B |
October 30, 2024 October 30, 2024 October 21, 2024 |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREImmix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB